Carlo
PeopleProgramsSpecialtiesInstitutionsPricing
Sign inJoin waitlistJoin the waitlist
Carlo

the ai that helps you match

Part of the Carlo family
© 2026 Carlo Finance, Inc.
PeopleProgramsSpecialtiesInstitutionsPricingMethodologyPrivacyTerms
Back to overview

Centennial Medical Center Internal Medicine

Residency · Nashville, TN

Sponsored by HCA Healthcare/TriStar Nashville · Director William Maynard

Research

Works by its people
2,659
Authors
69
First-author works
568
Citations
213,420
20112026

Topics

  • Lung Cancer Treatments and Mutations 160
  • Hematopoietic Stem Cell Transplantation 120
  • Cancer Immunotherapy and Biomarkers 119
  • Chronic Lymphocytic Leukemia Research 109
  • HER2/EGFR in Cancer Research 89
  • Cancer Genomics and Diagnostics 82
  • Multiple Myeloma Research and Treatments 81
  • CAR-T cell therapy research 80
  • Acute Myeloid Leukemia Research 77
  • Lymphoma Diagnosis and Treatment 76
  • Lung Cancer Research Studies 64
  • Advanced Breast Cancer Therapies 61

Most cited

  1. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

    The New England journal of medicine · 2021 · 2,130 citations · Jesus Berdeja

  2. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

    The New England journal of medicine · 2022 · 1,350 citations · Ian Flinn

  3. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.

    Lancet (London, England) · 2024 · 686 citations · Meredith Mckean

  4. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · 1,201 citations · David Spigel

  5. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

    Lancet (London, England) · 2021 · 1,514 citations · Jesus Berdeja

  6. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

    The New England journal of medicine · 2022 · 991 citations · Erika Hamilton

  7. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

    The New England journal of medicine · 2023 · 653 citations · Jesus Berdeja

  8. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.

    The New England journal of medicine · 2022 · 871 citations · Melissa Johnson